- $76.79m
- -$43.76m
- 48
- 44
- 24
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.7% | ||
| Return on Equity | -23.98% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 22.32 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Directors
- Richard Glickman NEC
- David Parkinson PRE (70)
- David Wood CFO (60)
- Peter Virsik COO
- Alessandra Cesano OTH
- Alex Martin DRC
- Scott Requadt DRC (53)
- Marella Thorell DRC (50)
- Franklin Berger IND (71)
- Gary Sollis IND (66)
- Sanford Zweifach IND (64)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 6th, 2009
- Public Since
- February 22nd, 2021
- No. of Employees
- 35
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 44,388,550
- Address
- 999 West Broadway, Suite 720, VANCOUVER, V5Z 1K5
- Web
- https://www.essapharma.com/
- Phone
- +1 7783310962
- Auditors
- Davidson & Co LLP
Upcoming Events for EPIX
Q3 2025 ESSA Pharma Inc Earnings Release
Similar to EPIX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the ESSA Pharma share price?
As of Today at 20:31 UTC, shares in ESSA Pharma are trading at $1.73. This share price information is delayed by 15 minutes.
How has the ESSA Pharma share price performed this year?
Shares in ESSA Pharma last closed at $1.73 and the price had moved by -75.11% over the past 365 days. In terms of relative price strength the ESSA Pharma share price has underperformed the S&P500 Index by -77.55% over the past year.
What are the analyst and broker recommendations for ESSA Pharma?
The overall consensus recommendation for ESSA Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ESSA Pharma dividend yield?
ESSA Pharma does not currently pay a dividend.
Does ESSA Pharma pay a dividend?
ESSA Pharma does not currently pay a dividend.
When does ESSA Pharma next pay dividends?
ESSA Pharma does not currently pay a dividend.
How do I buy ESSA Pharma shares?
To buy shares in ESSA Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ESSA Pharma?
As of the previous close price of $1.73, shares in ESSA Pharma had a market capitalisation of $76.79m.
Where are ESSA Pharma shares listed?
Here are the trading details for ESSA Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EPIX
What kind of share is ESSA Pharma?
Based on an overall assessment of its quality, value and momentum ESSA Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ESSA Pharma share price forecast for 2025?
The analyst consensus target price for shares in ESSA Pharma is $1.70. That is 1.49% below the last closing price of $1.73.
Analysts covering ESSA Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.69 for the next financial year.
Find out moreWhat is the trend in the ESSA Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ESSA Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +24.14%.
As of the last closing price of $1.73, shares in ESSA Pharma were trading -45.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ESSA Pharma PE Ratio?
The ESSA Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ESSA Pharma?
ESSA Pharma's management team is headed by:
- Richard Glickman - NEC
- David Parkinson - PRE
- David Wood - CFO
- Peter Virsik - COO
- Alessandra Cesano - OTH
- Alex Martin - DRC
- Scott Requadt - DRC
- Marella Thorell - DRC
- Franklin Berger - IND
- Gary Sollis - IND
- Sanford Zweifach - IND